|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.20 USD | -2.65% |
|
-1.42% | +14.51% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 33.3 | +60.5% | 12 | ||||||
| 820.72 | +20.88% | 27 | ||||||
| 287.95 | +21.14% | 19 | ||||||
| 2,052,158.8 | +47% | 24 | ||||||
| 96.64 | +13.19% | 16 | ||||||
| 225.45 | +7.91% | 31 | ||||||
| 48.26 | -23.57% | 19 | ||||||
| 113.82 | -2.43% | 22 | ||||||
| 101.47 | +24.72% | 25 | ||||||
| 487.5 | +4.66% | 12 | ||||||
| 105.2 | +31.01% | 22 | ||||||
| 280.39 | +18.29% | 20 | ||||||
| 87.73 | +46.22% | 26 | ||||||
| 361.67 | +5.82% | 9 | ||||||
| 458,000 | +65.64% | 5 | ||||||
| - | - | 61.5 | +20.39% | 1 | ||||
| 14.36 | +57.28% | 12 | ||||||
| 72.5 | +4.47% | 2 | ||||||
| 30.05 | +94.3% | 9 | ||||||
| 88.5 | -2.99% | 10 | ||||||
| Average | 125,673.79 | +25.72% | 16 | ||||||
| Weighted average by Cap. | 227,203.15 | +20.42% | 20 |
- Stock Market
- Stocks
- ZLAB Stock
- Sector Zai Lab Limited
- Sector consensus
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
